慢性心房颤动

Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011 Mar 15;123(10):e269-367.

• 全文
• 摘要

January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76.

• 全文
• 摘要

National Institute for Health and Care Excellence. Atrial fibrillation: management. June 2014 [internet publication].

• 全文

Lip GY, Skjøth F, Rasmussen LH, et al. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015 Apr 14;65(14):1385-94.

• 摘要

Kuck KH, Brugada J, Furnkranz A, et al; FIRE AND ICE Investigators. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016 Jun 9;374(23):2235-45.

• 全文
• 摘要

Luik A, Radzewtiz A, Kieser M, et al. Cryoballoon versus open irrigated radiofrequency ablation in patients with paroxysmal atrial fibrillation: the prospective, randomized, controlled, noninferiority FreezeAF Study. Circulation. 2015 Oct 6;132(14):1311-9.

• 全文
• 摘要

Sharma M, Cornelius VR, Patel JP, et al. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015 Jul 21;132(3):194-204.

• 全文
• 摘要

Del-Carpio Munoz F, Gharacholou SM, Munger TM, et al. Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation. Am J Cardiol. 2016 Jan 1;117(1):69-75.

• 全文
• 摘要

Lip GY, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest. 2014 Sep;146(3):719-726.

• 摘要

1.  Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011 Mar 15;123(10):e269-367.

• 全文
• 摘要

2.  Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893-962.

• 全文
• 摘要

3.  January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76.

• 全文
• 摘要

4.  Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005 Jun;36(6):1115-9.

• 全文
• 摘要

5.  Paciaroni M, Agnelli G, Caso V, et al. Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. J Thromb Haemost. 2005 Jun;3(6):1218-23.

• 全文
• 摘要

6.  Stewart S, Hart CL, Hole DJ, et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001;86:516-521.

• 全文
• 摘要

7.  Murdoch DL, O'Neill K, Jackson J, et al. Are atrial fibrillation guidelines altering management? A community based study. Scott Med J. 2005;50:166-169.

• 摘要

8.  Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N.

• 摘要

9.  Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949-953.

• 全文
• 摘要

10.  Singh SN, Tang XC, Singh BN, et al. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy. J Am Coll Cardiol. 2006;48:721-730.

• 摘要

11.  Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for the development of atrial fibrillation: the Framingham Heart Study Circulation. 2004;110:1042-1046.

• 全文
• 摘要

12.  Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution and gender of patients with atrial fibrillation: Arch Intern Med. 1995;155:469-473.

• 摘要

13.  Hobbs FD, Fitzmaurice DA, Jowett S, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess. 2005;9:1-74.

• 全文
• 摘要

14.  Murdoch DL, O'Neill K, Jackson J, et al. Are atrial fibrillation guidelines altering management? A community based study. Scott Med J. 2005;50:166-169.

• 摘要

15.  National Institute for Health and Care Excellence. Atrial fibrillation: management. June 2014 [internet publication].

• 全文

16.  Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997 Oct 7;96(7):2455-61.

• 全文
• 摘要

17.  Lip GY, Beevers DG. ABC of atrial fibrillation: history, epidemiology, and importance of atrial fibrillation. BMJ. 1995 Nov 18;311(7016):1361-3.

• 全文
• 摘要

18.  Allessie MA, Boyden PA, Camm AJ, et al. Pathophysiology and prevention of atrial fibrillation. Circulation. 2001 Feb 6;103(5):769-77.

• 全文
• 摘要

19.  Kannel WB, Abbott RD, Savage DD, et al. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J. 1983 Aug;106(2):389-96.

• 摘要

20.  Garrey WE. Auricular fibrillation. Physiol Rev. 1924;4:215-250.

21.  Moe GK, Rheinboldt WC, Abildskov JA. A computer model of atrial fibrillation. Am Heart J. 1964 Feb;67:200-20.

• 摘要

22.  Allessie MA, Bonke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The "leading circle" concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res. 1977 Jul;41(1):9-18.

• 全文
• 摘要

23.  Nattel S, Shiroshita-Takeshita A, Brundel BJ, et al. Mechanisms of atrial fibrillation: lessons from animal models. Prog Cardiovasc Dis. 2005 Jul-Aug;48(1):9-28.

• 摘要

24.  Cheung DW. Pulmonary vein as an ectopic focus in digitalis-induced arrhythmia. Nature. 1981 Dec 10;294(5841):582-4.

• 摘要

25.  Cheung DW. Electrical activity of the pulmonary vein and its interaction with the right atrium in the guinea-pig. J Physiol. 1981 May;314:445-56.

• 全文
• 摘要

26.  Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998 Sep 3;339(10):659-66.

• 全文
• 摘要

27.  Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of atrial fibrillation: the Framingham Study. N Engl J Med. 1982;306:1018-1022.

• 摘要

28.  Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham heart study. JAMA. 1994;271:840-844.

• 摘要

29.  Lokshyn S, Mewis C, Kuhlkamp V. Atrial fibrillation in coronary artery disease. Int J Cardiol. 2000;72:133-136.

• 摘要

30.  Chugh SS, Blackshear JL, Shen WK, et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol. 2001;37:371-378.

• 摘要

31.  Mukamal KJ, Tolstrup JS, Friberg J, et al. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation. 2005;112:1736-1742.

• 全文
• 摘要

32.  Koskinen P, Kupari M, Leinonen H. Role of alcohol in the recurrence of atrial fibrillation in persons less than 65 years of age. Am J Cardiol. 1990;66:954-958.

• 摘要

33.  Rich EC, Siebold C, Campion B. Alcohol-related acute atrial fibrillation: a case control study and review of 40 patients. Arch Intern Med. 1985;145:830-833.

• 摘要

34.  Chamberlain AM, Agarwal SK, Folsom AR, et al. Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. Heart Rhythm. 2011;8:1160-1166.

• 摘要

35.  Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010;95:186-193.

• 全文
• 摘要

36.  Lip GY, Beevers DG, Singh SP, et al. ABC of atrial fibrillation: aetiology, pathophysiology, and clinical features. BMJ. 1995;311:1425-1428.

• 全文
• 摘要

37.  Toft AD. Clinical practice: subclinical hyperthyroidism. N Engl J Med. 2001;345:512-516.

• 摘要

38.  Gami AS, Hodge DO, Herges RM, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol. 2007;49:565-571.

• 摘要

39.  Wang J, Liu L, Feng J, et al. Regional and functional factors determining induction and maintenance of atrial fibrillation in dogs. Am J Physiol. 1996;271:H148-H158.

• 摘要

40.  Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol. 1996;7:999-1007.

• 摘要

41.  Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation. 2004;109:327-334.

• 全文
• 摘要

42.  Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005 Jun 7;45(11):1832-9.

• 摘要

43.  Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005 Mar 1;45(5):712-9.

• 摘要

44.  Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006 May 16;47(10):1997-2004.

• 全文
• 摘要

45.  Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol. 2003 Dec 15;92(12):1379-83.

• 摘要

46.  Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol. 2003 Dec 1;92(11):1343-5.

• 摘要

47.  Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation. 2004 Jul 27;110(4):368-73.

• 全文
• 摘要

48.  Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation. 2006 Aug 15;114(7):e257-354.

• 全文
• 摘要

49.  Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014 Jun 26;370(26):2467-77.

• 全文
• 摘要

50.  Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014 Jun 26;370(26):2478-86.

• 全文
• 摘要

51.  Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864-70.

• 全文
• 摘要

52.  Yarmohammadi H, Varr BC, Puwanant S, et al. Role of CHADS2 score in evaluation of thromboembolic risk and mortality in patients with atrial fibrillation undergoing direct current cardioversion (from the ACUTE Trial Substudy). Am J Cardiol. 2012 Jul 15;110(2):222-6.

• 摘要

53.  Lip GY, Skjøth F, Rasmussen LH, et al. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015 Apr 14;65(14):1385-94.

• 摘要

54.  Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015 Feb 24;65(7):635-42.

• 摘要

55.  Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006 Mar;151(3):713-9.

• 摘要

56.  Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093-100.

• 摘要

57.  O'Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015 Dec 7;36(46):3258-64.

• 全文
• 摘要

58.  Gillis AM, Morck M. Atrial fibrillation after DDDR pacemaker implantation. J Cardiovasc Electrophysiol. 2002 Jun;13(6):542-7.

• 摘要

59.  Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018 Feb; 378(5):417-27.

• 全文
• 摘要

60.  Gillinov AM, Bagiella E, Moskowitz AJ, et al; CTSN. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med. 2016 May 19;374(20):1911-21.

• 摘要

61.  Chatterjee S, Sardar P, Lichstein E, et al. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol. 2013 Jan;36(1):122-33.

• 摘要

62.  Al-Khatib SM, Allen LaPointe NM, Chatterjee R, et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med. 2014 Jun 3;160(11):760-73.

• 全文
• 摘要

63.  Prystowsky EN. Assessment of rhythm and rate control in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2006 Sep;17 Suppl 2:S7-10.

• 摘要

64.  Lopes RD, Rordorf R, De Ferrari GM, et al. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018 Mar 13;71(10):1063-74.

• 全文
• 摘要

65.  Bressler R, Bahl JJ. Principles of drug therapy for the elderly patient. Mayo Clin Proc. 2003 Dec;78(12):1564-77.

• 摘要

66.  Opie LH. Adverse cardiovascular drug interactions. Curr Probl Cardiol. 2000 Sep;25(9):621-76.

• 摘要

67.  Roden DM. Antiarrhythmic drugs: from mechanisms to clinical practice. Heart. 2000 Sep;84(3):339-46.

• 全文
• 摘要

68.  Friedman PL, Stevenson WG. Proarrhythmia. Am J Cardiol. 1998 Oct 16;82(8A):50N-58N.

• 摘要

69.  Kuck KH, Brugada J, Furnkranz A, et al; FIRE AND ICE Investigators. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016 Jun 9;374(23):2235-45.

• 全文
• 摘要

70.  Luik A, Radzewtiz A, Kieser M, et al. Cryoballoon versus open irrigated radiofrequency ablation in patients with paroxysmal atrial fibrillation: the prospective, randomized, controlled, noninferiority FreezeAF Study. Circulation. 2015 Oct 6;132(14):1311-9.

• 全文
• 摘要

71.  Lafuente-Lafuente C, Valembois L, Bergmann JF, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2015;(3):CD005049.

• 全文
• 摘要

72.  Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 22007 Sep 6;357(10):987-99.

• 全文
• 摘要

73.  Le Heuzey J, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):597-605.

• 摘要

74.  Køber L, Torp-Pedersen C, McMurray JJ, et al; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. 2008 Jun 19;358(25):2678-87. [Erratum in: N Engl J Med. 010 Sep 30;363(14):1384.]

• 全文
• 摘要

75.  Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009 Feb 12;360(7):668-78.

• 全文
• 摘要

76.  Brønnum Nielsen P, Larsen TB, Gorst-Rasmussen A, et al. Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study. Chest. 2015 Jun;147(6):1651-1658.

• 全文
• 摘要

77.  Fang MC, Chen J, Rich MW. Atrial fibrillation in the elderly. Am J Med. 2007 Jun;120(6):481-7.

• 摘要

78.  Iqbal MB, Taneja AK, Lip GY, et al. Recent developments in atrial fibrillation. BMJ. 2005 Jan 29;330(7485):238-43.

• 全文
• 摘要

79.  National Institute for Health and Care Excellence. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. May 2012 [internet publication].

• 全文

80.  National Institute for Health and Care Excellence. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. March 2012 [internet publication].

• 全文

81.  National Institute for Health and Care Excellence. Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation. February 2013 [internet publication].

• 全文

82.  National Institute for Health and Care Excellence. Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation. September 2015 [internet publication].

• 全文

83.  Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51.

• 全文
• 摘要

84.  Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91.

• 全文
• 摘要

85.  Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014 Jul 8;130(2):138-46.

• 全文
• 摘要

86.  Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.

• 全文

87.  Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104.

• 全文
• 摘要

88.  Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012 Aug 1;110(3):453-60.

• 全文
• 摘要

89.  Caldeira D, Rodrigues FB, Barra M, et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart. 2015 Aug;101(15):1204-11.

• 摘要

90.  Sharma M, Cornelius VR, Patel JP, et al. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015 Jul 21;132(3):194-204.

• 全文
• 摘要

91.  Del-Carpio Munoz F, Gharacholou SM, Munger TM, et al. Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation. Am J Cardiol. 2016 Jan 1;117(1):69-75.

• 全文
• 摘要

92.  Gallego P, Roldán V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med. 2014 Nov;127(11):1083-8.

• 全文
• 摘要

93.  Lip GY, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest. 2014 Sep;146(3):719-726.

• 摘要

94.  National Institute for Health and Care Excellence. Atrial fibrillation quality standard. February 2018 [internet publication].

• 全文

95.  Vos MA, Golitsyn SR, Stangl K, et al; Ibutilide/Sotalol Comparator Study Group. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. Heart. 1998 Jun;79(6):568-75.

• 全文
• 摘要

96.  Oral H, Souza JJ, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med. 1999 Jun 17;340(24):1849-54.

• 全文
• 摘要

97.  Li H, Natale A, Tomassoni G, et al. Usefulness of ibutilide in facilitating successful external cardioversion of refractory atrial fibrillation. Am J Cardiol. 1999 Nov 1;84(9):1096-8, A10.

• 摘要

98.  Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001 May 10;344(19):1411-20.

• 全文
• 摘要

99.  Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018 Jan 1;20(1):e1-e160.

• 全文
• 摘要

100.  McKenna C, Palmer S, Rodgers M, et al. Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom. Heart. 2009 Apr;95(7):542-9.

• 全文
• 摘要

101.  Reynolds MR, Zimetbaum P, Josephson ME, et al. Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol. 2009 Aug;2(4):362-9.

• 全文
• 摘要

102.  Gillinov AM, Gelijns AC, Parides MK, et al. Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med. 2015 Apr 9;372(15):1399-409.

• 全文
• 摘要

103.  Phan K, Xie A, La Meir M, et al. Surgical ablation for treatment of atrial fibrillation in cardiac surgery: a cumulative meta-analysis of randomised controlled trials. Heart. 2014 May;100(9):722-30.

• 摘要

104.  Damiano RJ Jr, Gaynor SL, Bailey M, et al. The long-term outcome of patients with coronary disease and atrial fibrillation undergoing the Cox maze procedure. J Thorac Cardiovasc Surg. 22003 Dec;126(6):2016-21.

• 摘要

105.  Melby SJ, Kaiser SP, Bailey MS, et al. Surgical treatment of atrial fibrillation with bipolar radiofrequency ablation: mid-term results in one hundred consecutive patients. J Cardiovasc Surg (Torino). 2006 Dec;47(6):705-10.

• 摘要

106.  Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA. 2014 Feb 19;311(7):692-700.

• 全文
• 摘要

107.  Jons C, Hansen PS, Johannessen A, et al. The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-PAF) trial: clinical rationale, study design, and implementation. Europace. 2009 Jul;11(7):917-23.

• 全文
• 摘要

108.  Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005 Mar 8;111(9):1100-5.

• 全文
• 摘要

109.  Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008 Mar 25;117(12):1518-25.

• 全文
• 摘要

110.  Holmes DR, Reddy VY, Turi ZG, et al; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009 Aug 15;374(9689):534-42.

• 摘要

111.  Park JW, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv. 2011 Apr 1;77(5):700-6.

• 摘要

112.  Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol. 2013 Jul 9;62(2):108-118.

• 全文
• 摘要

113.  Carlson MD, Ip J, Messenger J, et al; Atrial Dynamic Overdrive Pacing Trial (ADOPT) Investigators. A new pacemaker algorithm for the treatment of atrial fibrillation: results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT). J Am Coll Cardiol. 2003 Aug 20;42(4):627-33.

• 摘要

114.  Kantharia BK, Freedman RA, Hoekenga D, et al; AOP Study Investigators. Increased base rate of atrial pacing for prevention of atrial fibrillation after implantation of a dual-chamber pacemaker: insights from the Atrial Overdrive Pacing Study. Europace. 2007 Nov;9(11):1024-30.

• 全文
• 摘要

115.  Saksena S, Prakash A, Ziegler P, et al; DAPPAF Investigators. Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing and antiarrhythmic drug therapy. J Am Coll Cardiol. 2002 Sep 18;40(6):1140-50.

• 摘要

116.  Holmqvist F, Kim S, Steinberg BA, et al. Heart rate is associated with progression of atrial fibrillation, independent of rhythm. Heart. 2015 Jun;101(11):894-9.

• 全文
• 摘要

117.  Batra G, Svennblad B, Held C, et al. All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart. 2016 Jun 15;102(12):926-33.

• 摘要

118.  Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98:476-484.

• 摘要

119.  Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-952.

• 全文
• 摘要

120.  Cooper HA, Bloomfield DA, Bush DE, et al. Relation between achieved heart rate and outcomes in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] Study). Am J Cardiol. 2004;93:1247-1253.

• 摘要

121.  Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004;43:241-247.

• 摘要

122.  Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol. 2003;42:185-197.

• 摘要

123.  Pawar PP, Jones LG, Feller M, et al. Association between smoking and outcomes in older adults with atrial fibrillation. Arch Gerontol Geriatr. 2012;55:85-90.

• 摘要

124.  Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000;35:183-187.

• 摘要

125.  Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007;6:981-993.

• 摘要

126.  Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689-2696.

• 全文
• 摘要

127.  Mant J, Hobbs, R, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493-503.

• 摘要

128.  Adderley NJ, Nirantharakumar K, Marshall T. Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies. BMJ. 2018 May 9;361:k1717.

• 全文
• 摘要

129.  Cappato R, Calkins H, Chen SA, et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol. 2009;53:1798-1803.

• 摘要

130.  Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310:2050-2060.

• 全文
• 摘要